Release Date: December 22, 2025
Expiration Date: December 22, 2026
Activity Overview
Intensive induction chemotherapy is the mainstay of front-line treatment for fit patients with acute myeloid leukemia (AML). Less intensive chemotherapy combinations, which are already standard of care for older patients and those with comorbidities, are currently under investigation in fit populations, as are all-oral formulations. Targeted therapies are being evaluated in patients with AML harboring FLT3, IDH1, NPM1, or KMT2A mutations.
This Community Practice Connections™ program provides an in-depth review of some of the key highlights from an Association of Cancer Care Centers virtual webcast series on current and emerging therapies in AML. This unique and engaging multimedia activity is ideal for the community-based clinician. It focuses on clinical trial data of targeted therapies and immunotherapy. The program is designed for those who did not attend the live meeting and to help reinforce learning for those who did.
Target Audience
This educational program is primarily directed toward community-based medical oncologists/hematologists, oncology nurses, advanced practice providers, and other health care professionals involved in the treatment of AML.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Implement personalized care plans for patients with acute myeloid leukemia (AML) aligned with guideline-recommended molecular testing and risk stratification protocols
- Assess emerging strategies for the management of patients with AML in the frontline and relapsed/refractory setting
- Devise effective strategies to monitor for and manage treatment-associated adverse events in patients with AML
Naval Daver, MD
Professor of Medicine
The University of Texas MD Anderson Cancer Center
Director, Leukemia Research Alliance Program
Houston, TX
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Agios, Amgen, Arog, Astellas, Bristol Myers Squibb, Celgene, Daiichi-Sankyo, Genentech, Gilead, ImmunoGen, Jazz, KITE, Novartis, Pfizer, Servier, Shattuck Labs, Stemline/Menarini, Syndax, Trillium; Grant/Research Funding (to institution): AbbVie, Amgen, Astellas, Bristol Meyers Squibb, Daiichi-Sankyo, FATE Therapeutics, Genentech, Gilead, GlycoMimetics, Hanmi, ImmunoGen, KITE, Novimmune, Pfizer, Servier, Trillium, Trovagene
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
